| Oct 15 |
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
|
| Oct 15 |
Castle Biosciences price target raised to $40 from $35 at BTIG
|
| Oct 9 |
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
|
| Oct 8 |
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
|
| Sep 24 |
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test
|
| Sep 17 |
Lucid Diagnostics to be deconsolidated from PAVmed's financial statements
|
| Sep 16 |
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements
|
| Sep 10 |
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress
|
| Sep 3 |
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health
|
| Aug 20 |
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer
|
